Melanoma Research Alliance

Leveraged Finance Fights Melanoma

Chaired by:

Clare Bailhé  Apollo MidCap
Brendan Dillon  UBS
Kerry Dolan  PSP Investments
Lee Grinberg  Elliott Management
George Mueller  KKR
AJ Murphy  Silver Lake

Geoff Oltmans  Silver Lake
Jeff Rowbottom  Iron Park Capital
Ian Schuman  Latham & Watkins
Cade Thompson  KKR
Trevor Watt  Hellman & Friedman
Celebrate the 9th annual
LEVERAGED FINANCE FIGHTS MELANOMA (LFFM)

COCKTAILS
Museum of Modern Art
18 West 54th Street, New York, NY
Wednesday, May 20, 2020
6:30 – 9:00 PM
Top Sponsors’ Private Pre-Event Reception begins at 6:00 PM

AFTERPARTY
Connolly’s Irish Pub
121 West 45th Street @ 6th Avenue
Generously donated by The Connolly Family
LEVERAGED FINANCE FIGHTS MELANOMA

WHO
The biggest names in the leveraged finance and private equity communities are gathering to raise funds to fight melanoma.

WHAT
Cocktails and networking for a good cause.

WHERE
Museum of Modern Art, 18 West 54th Street, NY, NY and afterparty at Connolly’s Irish Pub, 121 West 45th Street @ 6th Avenue.

WHEN
Wednesday, May 20, 2020
6:30 – 9:00 PM, afterparty to follow.

WHY
Melanoma is one of the fastest growing cancers worldwide, with rates of incidence increasing. In 2020, over 100,000 Americans are projected to be diagnosed. Learn how to protect yourself and your loved ones and support critical melanoma research.

HOW
Sponsor Leveraged Finance Fights Melanoma (LFFM) to benefit the Melanoma Research Alliance (MRA), the world’s largest non-profit funder of melanoma research.
LFFM SPONSORSHIP OPPORTUNITIES

$100,000+ PRESENTING SPONSORS
- Private pre-event reception access for 8 attendees
- Priority recognition as presenting sponsor on all event press releases, signage, and multimedia, including spotlight on event slide loop (8x)
- Includes 15 general tickets

$50,000 PLATINUM
- Private pre-event reception access for 4 attendees
- Platinum sponsor recognition on all event press releases, signage, and multimedia, including spotlight on event slide loop (4x)
- Includes 15 general tickets

$25,000 GOLD
- Private pre-event reception access for 2 attendees
- Gold sponsor recognition on all event press releases, signage, and multimedia, including spotlight on event slide loop (3x)
- Includes 10 general tickets

$12,500 PREFERRED
- Preferred sponsor recognition on all event press releases, signage, and multimedia, including spotlight on event slide loop (2x)
- Includes 10 general tickets

$7,500 ADVOCATE
- Advocate sponsor recognition on all event press releases, signage, and multimedia, including spotlight on event slide loop (1x)
- Includes 4 general tickets

Individual tickets are available for $300 each. All tickets, including sponsorships, receive a tax deduction above the value of $100 per ticket. Sponsorships are fully tax deductible if accepting no benefits.
LEVERAGED FINANCE FIGHTS MELANOMA

EVENT HISTORY AND RESEARCH SUPPORT
Since the inaugural event in 2012, the leveraged finance community has supported more than $13.1 million of melanoma research.

Recent landmark advances in melanoma treatment have provided new options for patients, and melanoma stands as the case study for state-of-the-art cancer drug development, precision medicine and immunotherapy. The data that melanoma scientists are generating is benefiting cancer researchers in many fields, including those studying bladder, brain, breast, colon, kidney, leukemia, lymphoma, lung, pancreatic, and prostate cancer.

2020 GOALS
Despite transformative progress over the last decade in melanoma research, about half of patients with advanced melanoma still do not respond to even the latest treatments. LFFM seeks to raise additional funds to advance research and educate attendees on the dangers of melanoma and importance of sun safety and early detection.
ABOUT THE MELANOMA RESEARCH ALLIANCE

The Melanoma Research Alliance (MRA) was launched in 2007 by Debra and Leon Black under the auspices of the Milken Institute. The organization aims to end suffering and death due to melanoma by collaborating with all stakeholders to accelerate powerful research, advance cures for all patients and prevent more melanomas. To date, MRA has committed $110 million in funding to more than 300 innovative research programs in 18 countries, with an additional $200 million leveraged from additional sources. Due to the generosity of its founders, 100% of donations go directly to research, no administrative or fund-raising costs at MRA or sponsored institutions.

LEGACY

Every hour, melanoma takes another life in the United States. But after decades of little progress, there is now hope. Since MRA began its work, 12 new treatments have become available to melanoma patients. MRA continues to catalyze strategic, collaborative, and accountable research efforts, moving the field toward effective treatment options for all melanoma patients as quickly as possible. With your support, we will see the day when no one suffers or dies from melanoma.

For more information about MRA, please visit www.CureMelanoma.org
Jamie Goldfarb didn’t think of herself as having cancer. Yes, she had been diagnosed with Stage II melanoma four years earlier and Stage III the following year, but the surgeries to remove it had been successful. The PET scans that followed had been normal. This wasn’t supposed to be happening.

Jamie was a new mom with an eleven-week old baby when she learned that not only was melanoma back, but it had progressed to Stage IV and spread to her liver and pancreas. Jamie was afraid, but was also determined to survive. For Jamie, it wasn’t a question of ‘if clinical trials were the right fit,’ it was a question of ‘which clinical trial.’ The right fit turned out to be the TIL trial at NCI. Two years after beginning treatment, Jamie was declared disease free.

"I would not be alive today, I mean hands down, without clinical trials. Stage IV melanoma had a 14% five-year survival rate at the time I was diagnosed. There were so few treatments. TIL treatment saved my life," says Jamie.
REGISTRATION

Contact Janine Rauscher, MRA Associate Director of Development at jrauscher@curemelanoma.org or 202.336.8944 to sponsor today and secure participation for your company. Individual ticket sales will formally go live at https://curemelanoma.org/lffm mid-March.

FOR ADDITIONAL EVENT INFORMATION, CONTACT:

Clare Bailhé
cbailhe@midcapfinancial.com

Brendan Dillon
Brendan.Dillon@ubs.com

Kerry Dolan
kdolan@investpsp.com

Lee Grinberg
LGrinberg@elliottmgmt.com

George Mueller
George.Mueller@kkr.com

AJ Murphy
aj.murphy@silverlake.com

Geoff Oltmans
geoff.oltmans@silverlake.com

Jeff Rowbottom
Jeff.rowbottom@ironparkcap.com

Ian Schuman
Ian.Schuman@lw.com

Cade Thompson
Cade.Thompson@kkr.com

Trevor Watt
Watt@hf.com
PRESS OPPORTUNITIES

LEVERAGED FINANCE FIGHTS MELANOMA will conduct outreach to secure media coverage in traditional and online publications of the event and the cause. The event will also be publicized on social media channels and the MRA website.

FOR PRESS OPPORTUNITIES, PLEASE CONTACT:

Cody Barnett
Director of Communications
cbarnett@curemelanoma.org or 202.336.8922